The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The closing price of Exact Sciences Corp (NASDAQ: EXAS) was $45.68 for the day, up 1.31% from the previous closing price of $45.09. In other words, the price has increased by $1.31 from its previous closing price. On the day, 2.87 million shares were traded. EXAS stock price reached its highest trading level at $46.5699 during the session, while it also had its lowest trading level at $45.0.
Ratios:
Our analysis of EXAS’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 10.07 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 50.99. For the most recent quarter (mrq), Quick Ratio is recorded 2.56 and its Current Ratio is at 2.89. In the meantime, Its Debt-to-Equity ratio is 1.03 whereas as Long-Term Debt/Eq ratio is at 1.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Mizuho on April 10, 2025, initiated with a Outperform rating and assigned the stock a target price of $60.
On March 13, 2025, RBC Capital Mkts started tracking the stock assigning a Sector Perform rating and target price of $52.
On January 23, 2025, Barclays started tracking the stock assigning a Overweight rating and target price of $70.Barclays initiated its Overweight rating on January 23, 2025, with a $70 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 13 ’25 when Doyle James Edward sold 1,485 shares for $42.02 per share. The transaction valued at 62,400 led to the insider holds 59,962 shares of the business.
Doyle James Edward bought 1,485 shares of EXAS for $62,400 on Aug 13 ’25. On Jul 16 ’25, another insider, Sebelius Kathleen, who serves as the Former Director of the company, bought 8,164 shares for $53.11 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EXAS now has a Market Capitalization of 8648092672 and an Enterprise Value of 10214820864. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.94 while its Price-to-Book (P/B) ratio in mrq is 3.50. Its current Enterprise Value per Revenue stands at 3.474 whereas that against EBITDA is 130.487.
Stock Price History:
The Beta on a monthly basis for EXAS is 1.05, which has changed by -0.23458445 over the last 52 weeks, in comparison to a change of 0.14064062 over the same period for the S&P500. Over the past 52 weeks, EXAS has reached a high of $72.83, while it has fallen to a 52-week low of $38.81. The 50-Day Moving Average of the stock is -8.88%, while the 200-Day Moving Average is calculated to be -12.33%.
Shares Statistics:
EXAS traded an average of 3.20M shares per day over the past three months and 5528120 shares per day over the past ten days. A total of 189.22M shares are outstanding, with a floating share count of 186.73M. Insiders hold about 1.37% of the company’s shares, while institutions hold 95.33% stake in the company. Shares short for EXAS as of 1753920000 were 6875496 with a Short Ratio of 2.15, compared to 1751241600 on 7015295. Therefore, it implies a Short% of Shares Outstanding of 6875496 and a Short% of Float of 4.1500002.
Earnings Estimates
Exact Sciences Corp (EXAS) is currently under the scrutiny of 7.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is $0.18, with high estimates of $0.21 and low estimates of $0.09.
Analysts are recommending an EPS of between $0.41 and $0.27 for the fiscal current year, implying an average EPS of $0.36. EPS for the following year is $1.09, with 7.0 analysts recommending between $1.41 and $0.75.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 22 analysts. It ranges from a high estimate of $815M to a low estimate of $804.6M. As of the current estimate, Exact Sciences Corp’s year-ago sales were $708.65MFor the next quarter, 22 analysts are estimating revenue of $826.81M. There is a high estimate of $836.71M for the next quarter, whereas the lowest estimate is $816.3M.
A total of 23 analysts have provided revenue estimates for EXAS’s current fiscal year. The highest revenue estimate was $3.17B, while the lowest revenue estimate was $3.14B, resulting in an average revenue estimate of $3.16B. In the same quarter a year ago, actual revenue was $2.76BBased on 24 analysts’ estimates, the company’s revenue will be $3.54B in the next fiscal year. The high estimate is $3.65B and the low estimate is $3.41B.
